Mauro Ferrari - 26 Dec 2025 Form 4 Insider Report for ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Reporting relationship: Director
Issuer ticker: ARWR
Reported as of: 26 Dec 2025
Net transaction value: -$527,100
SEC form: 4
Accepted by SEC: 30 Dec 2025, 17:46:28 UTC
Prior SEC filing: 18 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/Mauro Ferrari

Key filing fact

Mauro Ferrari filed Form 4 for ARROWHEAD PHARMACEUTICALS, INC. (ARWR) on 30 Dec 2025.

Key facts

This page summarizes Mauro Ferrari's Form 4 filing for ARROWHEAD PHARMACEUTICALS, INC. (ARWR).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 30 Dec 2025, 17:46.

Change

Previous filing in this sequence was filed on 18 Dec 2025.
Current net transaction value: -$527,100.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001506045 Primary reporting owner

Ferrari Mauro

Relationship: Director
Address: 177 E. COLORADO BLVD, SUITE 700, PASADENA
Signature: /s/Mauro Ferrari
Signature date: 30 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ARWR transaction

Common Stock

Sale

Transaction value: $527,100
Shares: -7,530
Change %: -9.8%
Price: $70.00
Shares after: 69,053
Date: 26 Dec 2025
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Footnote F2

Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.